On May 22, 2019, Arbutus Biopharma Corporation (the “Company”) held its 2019 Annual General Meeting of Shareholders (the “Annual Meeting”). As of April 17, 2019, the record date for the Annual Meeting, there were 56,850,172 common shares issued and outstanding and entitled to vote on the proposals presented at the Annual Meeting, of which 47,132,411, or 82.91%, were present in person or represented by proxy, which constituted a quorum.

At the Annual Meeting, the shareholders elected each of the Company’s nominees for director and approved the appointment of Ernst & Young LLP as the Company\’s independent registered public accounting firm for the fiscal year ending December 31, 2019. Set forth below are the final voting results for each of the proposals submitted to a vote of the Company’s shareholders at the Annual Meeting.

About Arbutus Biopharma Corporation (NASDAQ:ABUS)

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV). It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology. The Company’s lead RNAi HBV candidate, ARB-1467, eliminates HBV surface antigen expression in patients chronically infected with HBV. ARB-1467 is being developed as a multi-component RNAi therapeutic that targets various sites on the HBV genome. It is also developing small molecule covalently closed circular deoxyribonucleic acid (cccDNA) formation inhibitors, multiple small molecule orally bioavailable inhibitors of HBV surface antigen production and secretion, cccDNA epigenetic modifiers and stimulator of interferon genes agonists.